Kenjiro Aogi

10.3k total citations
150 papers, 2.9k citations indexed

About

Kenjiro Aogi is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Kenjiro Aogi has authored 150 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 56 papers in Cancer Research and 32 papers in Surgery. Recurrent topics in Kenjiro Aogi's work include Breast Cancer Treatment Studies (53 papers), Cancer Treatment and Pharmacology (45 papers) and HER2/EGFR in Cancer Research (41 papers). Kenjiro Aogi is often cited by papers focused on Breast Cancer Treatment Studies (53 papers), Cancer Treatment and Pharmacology (45 papers) and HER2/EGFR in Cancer Research (41 papers). Kenjiro Aogi collaborates with scholars based in Japan, United States and United Kingdom. Kenjiro Aogi's co-authors include Shigemitsu Takashima, Seigo Nakamura, Kenichi Inoue, Yasuo Ohashi, Taro Asaga, Hironobu Minami, Hiroji Iwata, Toru Watanabe, Carsten Goessl and Norio Kohno and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenjiro Aogi

142 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenjiro Aogi Japan 28 1.7k 818 699 573 521 150 2.9k
Hyun Hoon Chung South Korea 35 834 0.5× 433 0.5× 712 1.0× 489 0.9× 612 1.2× 169 4.3k
Enrique Grande Spain 35 2.5k 1.5× 608 0.7× 831 1.2× 1.2k 2.1× 1.1k 2.0× 286 4.6k
Jean‐Pierre Lotz France 26 1.6k 1.0× 447 0.5× 698 1.0× 699 1.2× 347 0.7× 119 2.8k
William M. Sikov United States 26 2.3k 1.4× 1.7k 2.1× 478 0.7× 660 1.2× 590 1.1× 93 3.4k
Toon Van Gorp Belgium 35 1.1k 0.7× 526 0.6× 1.3k 1.9× 389 0.7× 743 1.4× 219 4.8k
Barry C. Lembersky United States 31 2.5k 1.5× 1.1k 1.3× 663 0.9× 764 1.3× 276 0.5× 82 3.3k
Efrat Dotan United States 23 1.6k 1.0× 433 0.5× 1.2k 1.7× 681 1.2× 706 1.4× 134 2.9k
Bruno V. Sinn Germany 27 1.6k 0.9× 1.2k 1.4× 392 0.6× 523 0.9× 950 1.8× 88 3.2k
David Cosgrove United States 31 1.1k 0.7× 397 0.5× 788 1.1× 633 1.1× 713 1.4× 80 2.8k
Jean‐Paul Guastalla France 31 2.2k 1.3× 674 0.8× 521 0.7× 495 0.9× 621 1.2× 109 3.7k

Countries citing papers authored by Kenjiro Aogi

Since Specialization
Citations

This map shows the geographic impact of Kenjiro Aogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenjiro Aogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenjiro Aogi more than expected).

Fields of papers citing papers by Kenjiro Aogi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenjiro Aogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenjiro Aogi. The network helps show where Kenjiro Aogi may publish in the future.

Co-authorship network of co-authors of Kenjiro Aogi

This figure shows the co-authorship network connecting the top 25 collaborators of Kenjiro Aogi. A scholar is included among the top collaborators of Kenjiro Aogi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenjiro Aogi. Kenjiro Aogi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kogawa, Takahiro, Toshinari Yamashita, Takanori Ishida, et al.. (2024). Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). 3103–3103. 1 indexed citations
2.
Nakata, Eiji, Masaki Okamoto, Toshifumi Ozaki, et al.. (2023). Characteristics of Postoperative Patients with Breast Cancer Aged 65 Years and Older. Current Oncology. 30(1). 673–680.
3.
Nakata, Eiji, et al.. (2021). Influence of and Risk Factors for Axillary Web Syndrome Following Surgery for Breast Cancer.. Okayama University Scientific Achievement Repository (Okayama University). 1 indexed citations
4.
Mitobe, Yuichi, Kaori Iino, Ken‐ichi Takayama, et al.. (2020). PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of ESR1 and SCFD2. Cancer Research. 80(11). 2230–2242. 34 indexed citations
5.
Kubo, Makoto, Hiraku Kumamaru, Minoru Miyashita, et al.. (2020). Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer. 27(4). 511–518. 23 indexed citations
6.
Aogi, Kenjiro, et al.. (2019). Risk Factors for Lymphedema in Breast Cancer Survivors Following Axillary Lymph Node Dissection. Progress in Rehabilitation Medicine. 4(0). n/a–n/a. 10 indexed citations
7.
8.
Masuda, Norikazu, Hiroji Iwata, Kenjiro Aogi, et al.. (2016). Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Japanese Journal of Clinical Oncology. 46(12). 1088–1094. 6 indexed citations
9.
Hida, Akira I., Yasuaki Sagara, Daisuke Yotsumoto, et al.. (2016). Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Research and Treatment. 158(1). 1–9. 50 indexed citations
10.
11.
Toi, Masakazu, Shigehira Saji, Norikazu Masuda, et al.. (2011). Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Science. 102(4). 858–865. 38 indexed citations
12.
Aogi, Kenjiro, Masayuki Yoshida, Yoshiaki Sagara, et al.. (2010). The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemotherapy and Pharmacology. 67(5). 1007–1015. 9 indexed citations
13.
Ohta, Koji, Minoru Tanada, Takaya Kobatake, et al.. (2010). A Case of Colonic Liver Metastases with Macroscopic Intrabiliary Tumor Extension. The Japanese Journal of Gastroenterological Surgery. 43(12). 1234–1239.
14.
Matsumoto, Kunio, Chikako Shimizu, Tokuzo Arao, et al.. (2009). Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS. Journal of Proteome Research. 8(2). 457–462. 20 indexed citations
15.
Tsutani, Yasuhiro, Yoshiro Kubo, Minoru Tanada, et al.. (2006). Emergent Pancreaticoduodenectomy for the Hemorrhagic Pancreatic Pseudocyst Fenestrating into the Duodenum: A Case Report. The Japanese Journal of Gastroenterological Surgery. 39(2). 232–236. 1 indexed citations
16.
Tsutani, Yasuhiro, Shozo Ohsumi, Kenjiro Aogi, et al.. (2006). A case of metastatic Breast Cancer with HER2 gene amplification that responded completely to single agent trastuzumab. Breast Cancer. 13(4). 374–377. 3 indexed citations
17.
Aogi, Kenjiro, et al.. (1997). Usefulness of percutaneous microwave tissue coagulation therapy for solitary liver cancer. Journal of Microwave Surgery. 15. 85–88. 1 indexed citations
18.
Aogi, Kenjiro, et al.. (1996). Usefulness of the percutaneous transhepatic microwave tissue coagulation therapy for the liver tumor as a bedside treatment. Journal of Microwave Surgery. 14. 43–47. 4 indexed citations
19.
Murakami, Masakazu, Hiroyuki Soga, Kenjiro Aogi, et al.. (1989). A case of mesenteric panniculits of the sigmoid colon.. The Japanese Journal of Gastroenterological Surgery. 22(12). 2866–2869.
20.
Takiyama, Wataru, Kenjiro Aogi, Masakazu Murakami, et al.. (1989). A case of early esophageal cancer diagnosed as mucoepidermoid carcinoma.. The Japanese Journal of Gastroenterological Surgery. 22(11). 2677–2680. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyun Hoon Chung Breakdown of academic impact, for papers by Enrique Grande Breakdown of academic impact, for papers by Jean‐Pierre Lotz Breakdown of academic impact, for papers by William M. Sikov Breakdown of academic impact, for papers by Toon Van Gorp Breakdown of academic impact, for papers by Barry C. Lembersky Breakdown of academic impact, for papers by Efrat Dotan Breakdown of academic impact, for papers by Bruno V. Sinn Breakdown of academic impact, for papers by David Cosgrove Breakdown of academic impact, for papers by Jean‐Paul Guastalla
Rankless by CCL
2026